ArticleMolecular biotechnology2026
Elucidation of Bacterial-Mediated Hesperidin Transformation, Structural Evaluation, and Computational Drug Targeting against Helicobacter pylori.
Article in Molecular biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biotransformation, a dynamic process conducted by microorganisms, holds promise in modifying natural compounds for enhanced therapeutic potential. In this study, we leverage bacterial systems to catalyze the transformation of hesperidin, obtained from Citrus sinensis, aiming for structural modifications that could optimize its bioactivity and computational targeting against Helicobacter pylori. Multiple bacterial species were employed to perform biotransformation reactions. HPLC and FTIR analyses were used to determine structural modifications and bio-transformed products. The reaction in which hesperidin metabolite was formed was catalyzed by Bacillus spp. The transformed products, along with the original compound, underwent rigorous bioactivity testing to evaluate their potential in combating oxidative stress, inflammation, and diabetes. Employing well-established in vitro methods, we assessed the bio-transformed derivatives for antioxidant efficacy, revealing an impressive 94% inhibition of free radicals compared to hesperidin. In terms of anti-inflammatory activity, the results showcased a substantial 92% inhibition, while the assessment of antidiabetic activity demonstrated a notable 85% inhibition. The hesperidin metabolites were more active than hesperidin in biological activity evaluations. So, the bio-transformed compound derived from hesperidin, along with pure compound, was used to design a computational drug targeting the bacterium H. pylori. Among these two compounds, the bio-transformed product of hesperidin with an alkyl amine exhibited the highest docking energy of - 180.26 kJ/mol, as compared to pure compound. SwissADME provided valuable insights into the compound's drug-likeness like 0.55 bioavailability and 8.41 synthetic accessibility. ProTox-II evaluated different toxicity endpoints with a 0.96 probability of being inactive in cytotoxicity. These findings support the potential of the bio-transformed compound as a promising candidate for further investigation and development as a drug against H. pylori.
Indexed as
Identifiers
39992485What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.